



## UB Center for Advanced Technology in Big Data and Health Sciences (UB CAT)

# Where winning partnerships in health sciences and big data start

## What is UB CAT?

The University at Buffalo Center for Advanced Technology in Big Data and Health Sciences (UB CAT) is a project cost-sharing grant program funded by Empire State Development, and designed to drive the growth of life and health science businesses in New York State.

By partnering with a University at Buffalo investigator, New York State companies can access matching funds for collaborative product development or proof of concept research in the health sciences, especially in the areas of drug development, medical devices, diagnostic tools and healthcare IT. Preference will be given to projects that involve or enable Big Data applications.

## Why UB CAT?

Health science companies can benefit from: project cost-sharing; outstanding faculty expertise; state-of-the-art facilities and equipment; and access to SUNY's reduced rates on services and supplies.

## ELIGIBILITY & REQUIREMENTS

- Proposed projects must align with UB CAT's focus areas (big data and health sciences)
- Company is registered in NYS and has an office location in NYS
- Company has at least 1 full time employee
- Company has available matching funds for project cost sharing
- Commitment of a University at Buffalo Principal Investigator\*
- Scientific, technical, and innovative merit
- Demonstrated need for support of project
- Appropriateness of budget items within UB CAT project guidelines
- Ability to successfully complete project in one fiscal year (July-June of the project year)
- Potential economic impact for New York State\*\*
- Appropriateness of budget items within UB CAT project guidelines

*\* All projects are subject to State University of New York intellectual property policies. See reverse side for special SWIFT for CAT preferred terms.*

*\*\* Companies that receive CAT funding are required to provide annual economic impact reports for five years. Information on eligible economic impacts and reporting is available upon request.*



**UB SWIFT FOR UB CAT** Preferred Terms for UB CAT Companies



University at Buffalo

New York State Center of Excellence  
Bioinformatics and Life Sciences

Business and Entrepreneur Partnerships

[buffalo.edu/cbls/cat](http://buffalo.edu/cbls/cat)

rev031720

## What is UB SWIFT?

The University at Buffalo values the mutual benefits of academic-industry collaborations and understands that efficient transactions and financial certainty are important to business. The SWIFT approach empowers both entities to set research and licensing terms at the project planning stage, reducing transaction time and eliminating lengthy, costly negotiations from the partnering process.



## Why UB SWIFT for UB CAT?

UB offers a special version of UB SWIFT preferred exclusive license terms for UB CAT companies as an alternative to the UB Standard Option (see comparison):

- The SWIFT upfront Preferred Terms Fee is waived (\$0)
- The cumulative net sales amount before royalty payments are reduced by 20%, but all other SWIFT benefits remain
- SWIFT terms are subject to PI approval

For additional questions pertaining to UB SWIFT for UB CAT, contact:

-----o **Jennifer Mandina, JD, MS**  
Associate Manager, Contracts  
716-645-8952 | mandina@buffalo.edu

## UB CAT with Industry Focused Terms

STANDARD	UB SWIFT	UB SWIFT FOR UB CAT
<p>PREFERRED TERMS FEE</p> <p><b>Negotiated</b></p>	<p>10% of the contract budget or \$15,000, whichever is greater</p>	<p>\$0. The Preferred Terms Fee is waived for UB CAT funded projects.</p>
<p>ROYALTY RATE</p> <p><b>Negotiated</b></p>	<p>1% after exceeding \$50M in cumulative net sales if market entry requires human trials and regulatory approval; or</p> <p>1% after exceeding \$20M in cumulative net sales for all other technology</p>	<p>1% after exceeding \$40M in cumulative net sales if market entry requires human trials and regulatory approval; or</p> <p>1% after exceeding \$16M in cumulative net sales for all other technology</p>
<p>LICENSE ISSUE FEE</p> <p><b>Negotiated</b></p>	<p>None</p>	<p>None</p>
<p>MIN. ANNUAL ROYALTIES</p> <p><b>Negotiated</b></p>	<p>None</p>	<p>None</p>
<p>COMPANY DUE DILIGENCE MILESTONES</p> <p><b>Negotiated</b></p>	<p>None <i>(unless the project includes federal funding)</i></p>	<p>None <i>(unless the project includes federal funding)</i></p>
<p>SUBLICENSING</p> <p><b>Negotiated</b></p>	<p>Granted</p>	<p>Granted</p>
<p>PATENT PROSECUTION MANAGEMENT</p> <p><b>Negotiated</b></p>	<p>Company Manages</p>	<p>Company Manages</p>